Cytek Biosciences Inc (NAS:CTKB)
$ 5.6 0.03 (0.54%) Market Cap: 735.13 Mil Enterprise Value: 479.43 Mil PE Ratio: 0 PB Ratio: 1.87 GF Score: 60/100

Cytek Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 04:15PM GMT
Release Date Price: $8.34 (-1.65%)
Fawzi Kawash JPMorgan;Analyst

Hello all and welcome. My name is Fawzi Kawash. I'm associate at JPMorgan. It's my pleasure to introduce Dr. Jiang of Cytek.

Wenbin Jiang Cytek Biosciences
Inc. - CEO & Chairman

Good morning. Thanks to JPMorgan for inviting us to present you Cytek Biosciences. As usual, the Safe Harbor statement, I'm not going to read through.

So Cytek is a cell analysis company. We build our business based on our foundational four business pillars, which includes: instrument, applications, bioinformatics, and clinical. I'm going to get into details of all those points in the following presentation.

To start with, I'm going to give you a summary of our performance. Cytek, in 2016, we launched our first product, Athena, which is a conventional flow cytometer. A year later, we launched Cytek Aurora, our flagship product based on the full spectral flow technology, which is a cell analyzer. And a year later, we launched the Northern Lights, which helped to serve the entry-level applications in the cell analysis.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot